Skip to content
ESPT
MARKETS / NASDAQ / Health care / Medical devices and instruments / SMTI
NASDAQ · ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES · SMALL CAP

Sanara MedTech Inc. SMTI

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$103.1M
▲ 19.0% YoY
$-37.6M
$2.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Sanara MedTech Inc. primarily markets and sells soft tissue repair and bone fusion products for use in the operating room or other sterile environments. As of December 31, 2025, it had a staff of 108 full-time employees. Following the disposal of its Tissue Health Plus platform, it now has a single reportable segment. Its soft tissue repair products include CellerateRX Surgical Powder, a hydrolyzed collagen that aids in the management of surgical wounds, and BIASURGE Advanced Surgical Solution, a sterile no-rinse, advanced surgical solution used for wound irrigation. Its bone fusion products include BiFORM Bioactive Moldable Matrix, an osteoconductive, bioactive, porous implant that allows for bony ingrowth across the graft site, and ALLOCYTE Plus Advanced Viable Bone Matrix, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers. It was incorporated in Texas on December 14, 2001.

Written from the business description in Sanara MedTech Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 24 March 2026. Every sentence was checked against that document before publication.

Growth

USD 103.1M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 103.1 · Net income -37.6
50M100M-15M-30M
201020132016201920222025
Compound annual growth
+31.0%
+45.9%
+40.8%
+37.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +45.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−36 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating 7.1% · Net -36.4%
-200%-400%-600%
201020172025
ROE
FY2025 · ROE -165.7%
-500%-1000%
201020172025
Three returns, three denominators.
Gross margin92.7%
Operating margin7.1%
Net margin-36.4%
EBITDAUSD 11.3M

Each USD of equity lost 166 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 2.2
1M2M-2M-4M
201020172025
Dividends paid·
Net buybacks·
Share of profit·
Consecutive raises·

Total assetsUSD 72.9M
EquityUSD 5.9M
CashUSD 16.6M
Gross debtUSD 46.0M
Net debtUSD 29.4M
Current ratio1.80×

Net debt stands at 495% of equity.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SMTI, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.10.10.10.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B0.00.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0◌◌−0.0−0.0−0.0
EBITDA $B0.00.0−0.0−0.0−0.0−0.0−0.0◌◌◌◌◌◌−0.0−0.0−0.0
Income tax $B◌0.0◌−0.0◌0.00.00.00.00.00.00.00.0◌◌◌
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.0−0.0−0.0−0.0◌◌◌
EPS, diluted $−4.36−1.14−0.52−1.00−1.08−0.76−1.320.000.00−0.01−0.02−0.03−0.05−0.03−0.23−0.19
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %−165.7−22.9−9.9−21.9−43.1−69.6−78.2−174.2———————−1190.7
Shares out B0.010.010.010.010.010.010.000.000.110.110.110.090.090.070.060.04

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 78 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Three checks were skipped: EPS is not tagged before 2010. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityOrthopedic, Prosthetic & Surgical Appliances & Supplies
Listed onNASDAQ
Incorporated inTexas
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image